EPIX

Analyst Sentiment

Wall St. Consensus
Buy
4 analysts·Low coverage
63
Score
2 Buy (50%)2 Hold (50%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
250%
Hold
250%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$2.00
+894.0%
Consensus
$9.50
+4621.7%
Bull
$17.00
+8349.3%
12-Month Target Range4 analysts
$2.00$9.50$17.00
Current $0.20Consensus
Current Price
$0.20
Upside to Consensus
$9.30

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev
EPS
FY2028
Rev
EPS
FY2029
Rev
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029E
Revenue Avg$22M$45M
Low$22M$45M
High$22M$45M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-22M$-22M$-21M$-7M
Low$-22M$-22M$-21M$-7M
High$-22M$-22M$-21M$-7M
EPS Avg$-0.49$-0.49$-0.48$-0.16
Low$-0.49$-0.49$-0.48$-0.16
High$-0.49$-0.49$-0.48$-0.16
Analysts (Rev / EPS)1 / 1 / 11 / 1 / 1
Quarterly
MetricQ3 2026
Revenue Avg
Low
High
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-2M
Low$-2M
High$-2M
EPS Avg$-0.04
Low$-0.04
High$-0.04
Analysts (Rev / EPS) / 1

Earnings Surprises

Recent Analyst Actions

Nov 4, 2024Piper Sandler
Piper Sandler Downgrades ESSA Pharma (EPIX) to Neutral
Target:$2.00
+22.7%from $1.63
Sep 16, 2024Oppenheimer
Oppenheimer Reiterates Outperform Rating on ESSA Pharma (EPIX)
Target:$17.00
+148.2%from $6.85
Sep 16, 2024Piper Sandler
Piper Sandler Reiterates Overweight Rating on ESSA Pharma (EPIX)
Target:$15.00
+119.0%from $6.85
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.